Navigation Links
Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering
Date:11/6/2009

SAN DIEGO, Nov. 6 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by the Company.

Credit Suisse Securities (USA) LLC is acting as sole book-running manager, Piper Jaffray & Co. is acting as co-lead manager and Canaccord Adams Inc. and JMP Securities are acting as co-managers for the offering. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from Credit Suisse Securities (USA) LLC, Prospectus Department, One Madison Avenue, 1B, New York, NY 10010, Phone: (800) 221-1037.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Trius Therapeutics

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections.

SOURCE Trius Therapeutics, Inc.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Trius Torezolid Antibiotic for the Treatment of Severe Skin Infections Featured at ICAAC Meeting
2. Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
3. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
4. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
5. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
6. Trius Doses First Patient in Antibacterial Phase 2 Trial
7. PacificGMP Completes GMP Product Fill for Trius Therapeutics
8. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
9. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
10. Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients
11. Echo Therapeutics Announces Significant Advance in Development of its One-Piece, Needle Free Symphony tCGM Biosensor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... 29, 2016 ReportsnReports.com adds ... market research report that provides an overview of ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
(Date:4/28/2016)... April 28, 2016   Click here for ... Inc. (NYSE: DPLO), the nation,s largest independent specialty ... definitive agreement to acquire Valley Campus Pharmacy, Inc., ... a leading specialty pharmacy that provides individualized patient ... . In 2015, TNH generated approximately $400 ...
(Date:4/28/2016)... 2016  The blood testing market in ... Kalorama Information and The Freedonia Group in a recent ... testing.  The healthcare research firm said that ... collection stations and in improving testing at the provincial ... Blood Testing Market in China , ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... , ... East Los Angeles dentist , Dr. Ramin Assili, is now ... receive any dental extraction treatment for $40 off the regular price. This promotion cannot ... lower price, patients can more easily afford extractions to eliminate teeth that are damaged ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... Further establishing ... to announce that the new WHIMZEES Variety Value Boxes were selected from over 1,000 ... Product Showcase Award. , WHIMZEES natural dental chews for dogs are a favorite ...
(Date:5/2/2016)... , ... May 02, 2016 , ... ... itself around major organs, such as the kidneys, liver and pancreas. If not ... M.D ., a board-certified physician in Internal Medicine, Medical Oncology and Palliative Care, ...
(Date:5/2/2016)... ... 2016 , ... According to an American Psychological Association article, the ... before the age of 18. Of those who survive, many still face effects as ... , In her new book, Lyah! Lyah! Pants on Fyah!, she shares stories from ...
(Date:5/2/2016)... ... 2016 , ... TeleMedCo™, a new company developing real time ... the rapid diagnosis, triage and admission of patients leveraging IBM Watson’s software and ... for the first time at GENBAND’s Perspectives16 conference. , TeleMedCo selected GENBAND’s ...
Breaking Medicine News(10 mins):